advertising
How to present like a pro, even if it doesn't come naturally
As of February, the Washington economy is holding up very well compared with the national economy....
Dendreon's stock woes may have been unpredictable, but biotech firms often face steep odds.
Even as the economy trends downward, restauranteurs bet our hunger for red meat will grow
Flip: How to Turn Everything You Know on Its Head -- and Succeed Beyond Your Wildest Imaginings
By...
Janis Machala is founder and managing partner of Paladin Partners, an executive search and business...
Horse raising becomes less cost-effective in an economic downturn
A new biotechnology company being launched out of Accelerator Corp., a business incubator in Seattle, is seeking to commercialize technology developed at Washington State University. Commercializing university research is not unusual for a start-up, except that this time, the biotech coming out of Pullman is expected to lead to cancer treatment for humans. This is a first for the landgrant university, whose traditional areas of expertise are in agricultural, veterinary and bioenergy sciences rather than human-based biomedical science. The technology is expected to yield therapies that arrest the spread of cancerous tumors. Research director for the start-up company, Recodagen, will be J. Suzanne Lindsey, the WSU researcher who first developed the technology. Recodagen has raised an undisclosed amount of initial seed funding, making it the first venture-funded start-up to come out of WSU's technology licensing program.
Print
Email